Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of APL-1501 ER vs APL-1202 IR in Healthy Volunteers
NCT06034015Phase 1Unknown
- Sponsor
- Asieris Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nitroxoline in bladder cancer (2 arms), sponsored by Asieris Pharmaceuticals. Primary endpoints: Adverse Events (AEs), Serious Adverse Events (SAEs) and 1 more. Status: unknown.
02
Drugs
nitroxoline
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06034015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034015.